---
title: "SPIEGELMAN DANIEL K — Ownership Dossier"
canonical: https://whiteintel.dev/entity/3552c0b8-712d-5b45-aeea-de313c2fcf8e
json: https://whiteintel.dev/api/public/dossier/3552c0b8-712d-5b45-aeea-de313c2fcf8e
identifier: sec:0001238403
jurisdiction: US
risk: Low
source: WhiteIntel corporate-ownership graph
---

# SPIEGELMAN DANIEL K

**Type:** Person  
**Jurisdiction:** [US](https://whiteintel.dev/jurisdictions/us)  
**Identifier:** `sec:0001238403`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/3552c0b8-712d-5b45-aeea-de313c2fcf8e  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/3552c0b8-712d-5b45-aeea-de313c2fcf8e  

## Ownership & control

### Holdings / subsidiaries

- **Maze Therapeutics, Inc.** (director) — https://whiteintel.dev/entity/dd91eb35-a8ad-5def-97d9-315d460750d5
- **CV THERAPEUTICS INC** (officer) — https://whiteintel.dev/entity/9858d70c-e1a7-56b0-98de-93432192d06a
- **vTv Therapeutics Inc.** (director) — https://whiteintel.dev/entity/353f31f2-6045-5ec1-8144-e0547fb20612
- **SPRUCE BIOSCIENCES, INC.** (director) — https://whiteintel.dev/entity/d5754a2c-1f5a-5d85-95bc-cfd048f11503
- **Maze Therapeutics, Inc.** (director) — https://whiteintel.dev/entity/dd91eb35-a8ad-5def-97d9-315d460750d5
- **Kyverna Therapeutics, Inc.** (director) — https://whiteintel.dev/entity/f0d67aac-4707-507f-88b3-33747c372407
- **MYRIAD GENETICS INC** (director) — https://whiteintel.dev/entity/7a32b75c-a965-5188-aa17-f64a661f8b02
- **JIYA ACQUISITION CORP.** (director) — https://whiteintel.dev/entity/228ed576-0d79-59dc-a084-a10c71c02530
- **BIOMARIN PHARMACEUTICAL INC** (officer) — https://whiteintel.dev/entity/da243f5f-5fb4-5808-b258-c3726f1bb8cb
- **BIOMIRA CORP** (director) — https://whiteintel.dev/entity/82b3cb4c-4e01-50d7-99f6-0eb90587fb53
- **RELYPSA INC** (director) — https://whiteintel.dev/entity/e8b00180-23b6-519b-8d25-65fd27072755
- **ANTHERA PHARMACEUTICALS INC** (director) — https://whiteintel.dev/entity/e045f694-438c-5a8e-85e4-8681774f40b6
- **AFFYMAX INC** (director) — https://whiteintel.dev/entity/fff6ce45-e5e5-5912-a5e1-b5af738ecae0
- **OMEROS CORP** (director) — https://whiteintel.dev/entity/83b1a024-7f59-51d6-8699-957dcd21f5f7
- **Cyclacel Pharmaceuticals, Inc.** (director) — https://whiteintel.dev/entity/2b640b7c-3e03-51c2-81e3-83fb45882268

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **SPIEGELMAN DANIEL K**. Human view: https://whiteintel.dev/entity/3552c0b8-712d-5b45-aeea-de313c2fcf8e · Structured JSON: https://whiteintel.dev/api/public/dossier/3552c0b8-712d-5b45-aeea-de313c2fcf8e._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._